Prosecution Insights
Last updated: November 04, 2026

Glaxosmithkline Intellectual Property (No 3) Limited

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Analysis

Glaxosmithkline Intellectual Property (No 3) Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. With only 1 pending office action, the company's current prosecution activity for this specific entity is highly concentrated. The technical requirements of the Biotechnology & Pharmaceuticals area are being addressed by a single point of contact at the patent office.

The busiest examiner for this portfolio is HUTTER, GILLIAN A, who is currently handling 1 pending office action. Because the total number of pending office actions is 1, HUTTER, GILLIAN A is the only examiner currently reviewing the applications for this entity. The prosecution of this 1 pending office action within 1 distinct art unit allows for a very focused legal strategy. Practitioners should tailor their approach to the specific tendencies of HUTTER, GILLIAN A within the Biotechnology & Pharmaceuticals technology area to resolve the 1 pending office action. This 1 distinct art unit provides the primary organizational context for the current filing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUTTER, GILLIAN A 1 54.8% +45.3%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18665688 TREATMENT OF PRURITUS WITH P2X3 MODULATORS HUTTER, GILLIAN A —

Top Art Units

Art UnitApps
1625 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18665688 TREATMENT OF PRURITUS WITH P2X3 MODULATORS HUTTER, GILLIAN A 1625 §102§103DP Non-Final OA — Pending May 16, 2024

Managing Glaxosmithkline Intellectual Property (No 3) Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Glaxosmithkline Intellectual Property (No 3) Limited have?

Glaxosmithkline Intellectual Property (No 3) Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Glaxosmithkline Intellectual Property (No 3) Limited applications?

Gillian A Hutter has the most, with 1 of Glaxosmithkline Intellectual Property (No 3) Limited's pending office actions.

What technology area are Glaxosmithkline Intellectual Property (No 3) Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month